Shares surge in the public market debuts of Livongo and Health Catalyst
Both Livongo and Health Catalyst held their IPOs today and saw their stock price soar more than 40 percent in early trading.
Both Livongo and Health Catalyst held their IPOs today and saw their stock price soar more than 40 percent in early trading.
The chronic disease management company filed its S-1 paperwork on Friday, joining Change Healthcare, Phreesia and Health Catalyst as part of the raft of companies planning to go public after a nearly three year IPO drought in digital health.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company, which will be listed on the Nasdaq exchange under the ticker symbol "LVGO," offers tech-enabled solutions that help to monitor and manage people with chronic conditions like diabetes, hypertension and behavioral health issues.
With the new feature, members have the ability to link their Apple, Fitbit or Samsung smartwatches to the company's app to receive health information on their wrist and share activity information back with Livongo to better personalize activity and health suggestions.
According to the company's prospectus, Phreesia's platform facilitated more than 54 million patient visits for approximately 50,000 individual providers and processed more than $1.4 billion in payments over the course of FY 2019.
The San Francisco company offers personalized health coaching and therapy to help users better manage their physical and mental chronic health conditions like anxiety, asthma, COPD, diabetes, depression and hypertension.
Patients who also had another chronic disease, were using insulin daily to manage their Type 2 Diabetes or had lived with diabetes for more than two years were more likely to have a positive effect on empowerment measurements.
MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company's new products, emerging business lines and how collaboration with other companies have driven recent innovation.
The new product represents one of the first major expansions of the company's behavioral health offerings since the company's acquisition of Denver-based behavioral health startup myStrength earlier this year.
Beginning in June, the Livongo for Diabetes program will be available to Medicare Advantage members of Cambia Health Solutions' regional health plans.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
In an interview, Livongo Chief Commercial Officer Jim Pursley discussed how the company has moved beyond its initial focus of diabetes management to other conditions that may overlap with the needs of its members, such as hypertension and its recent move into behavioral health.
While the skills can help facilitate smoother patient engagement, there's still work to do when it comes to bringing voice to healthcare.
Less than two months after MedCity speculated whether Amazon would release a HIPAA-compliant Echo device, the tech giant revealed Thursday that select skills for Alexa — the voice-activated personal assistant service powering those devices — are indeed HIPAA-compliant.
Rock Health's latest report found that in the first quarter of 2019, $986 million was invested across digital health deals, which is a little more than half the amount that was raised in Q1 2018.
Through the collaboration, Hello Heart will offer its customers LifeScan's OneTouch line of connected glucose monitors and test strips which can upload results automatically onto the company's platform.